News coverage about Global Blood Therapeutics (NASDAQ:GBT) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Global Blood Therapeutics earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media stories about the company an impact score of 43.7928388787094 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Hot Stock Analysis – Global Blood Therapeutics Inc., (NASDAQ: GBT) – Stock Watch (stocksnewstimes.com)
- Global Blood Therapeutics (GBT) Receives “Outperform” Rating from Wedbush (americanbankingnews.com)
- Beta as a Common Measure of Risk – Global Blood Therapeutics Inc., (NASDAQ: GBT) – Stock Watch (stocksnewstimes.com)
- Glowing Stock’s Review – Global Blood Therapeutics Inc (NASDAQ: GBT) – Alpha Beta Stock (alphabetastock.com)
- GBT seeks $216M to drive sickle cell trials (bioworld.com)
GBT has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Wedbush restated an “outperform” rating and issued a $73.00 price target on shares of Global Blood Therapeutics in a research report on Friday, December 15th. Nomura increased their price objective on shares of Global Blood Therapeutics to $91.00 and gave the stock a “buy” rating in a research report on Monday, December 11th. Oppenheimer set a $79.00 price objective on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Finally, Cantor Fitzgerald set a $61.00 price objective on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $69.00.
Global Blood Therapeutics (GBT) traded up $0.35 on Wednesday, hitting $54.10. 751,034 shares of the stock traded hands, compared to its average volume of 975,212. The firm has a market capitalization of $2,550.00 and a PE ratio of -19.67. Global Blood Therapeutics has a 52 week low of $24.02 and a 52 week high of $68.05.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.22). equities research analysts expect that Global Blood Therapeutics will post -3.61 EPS for the current fiscal year.
In other Global Blood Therapeutics news, insider Peter Radovich sold 15,000 shares of the firm’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $50.00, for a total value of $750,000.00. Following the completion of the sale, the insider now directly owns 17,684 shares in the company, valued at $884,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jung Choi sold 3,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $62.95, for a total transaction of $188,850.00. Following the completion of the sale, the insider now owns 140,877 shares of the company’s stock, valued at $8,868,207.15. The disclosure for this sale can be found here. Insiders sold 54,911 shares of company stock valued at $3,059,552 over the last 90 days. Corporate insiders own 5.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was reported by Equities Focus and is the property of of Equities Focus. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.equitiesfocus.com/2018/03/14/global-blood-therapeutics-gbt-receiving-somewhat-positive-media-coverage-study-shows.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.